The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer

International Urology and Nephrology

Volumn 34, Issue 4, 2002, Pages 519-523

  Erdem, Erim ^a   Atsü, Necmettin ^a   Akbal, Cem ^a   Bilen, Cenk Y ^a   Ergen, Ali ^a   Özen, Haluk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Free to Total PSA ratio; Pathological features; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OUTCOMES RESEARCH; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SERUM;

BIOPSY, NEEDLE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0141956082     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025685718493     Document Type: Article

References (17)

1. Ackerman DA, Barry JM, Wicklend RA et al. Analysis risk factors associated with prostate cancer extension to the surgical margin and pelvic lymph node metastasis at radical prostatectomy. J Urol 1993; 150: 1845-1850.
2. Arcengeli CG, Shepherd L, Smith DS et al. Correlation of percent free PSA with pathologic features of prostatic carcinoma. J Urol 1996; 155: 420A.
3. Blackwell KL, Bosstwick DG, Myers RP et al. Combining prostate specific antigen with cancer and gland volume to predict more reably pathological stage: The influence of prostate specific antigen density. J Urol 1994; 151: 1565-1570.
4. Blustein DL, Bostwick DG, Bergralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151: 1315-1320.
5. Bostwick DG, Quin J, Bergstralh E et al. Prediction of capsular perforation and seminal vesicul invasion in prostate cancer. J Urol 1996; 155: 1361-1367.
6. Firat D, Hayran M. Cancer Statistics in Turkey and in the World (1990-1992). 1st Edition. Turkish Association for Cancer Research and Control 1995: 16-41.
7. Graefen M, Hammerer P, Henke P et al. Percentage of free PSA does not correlate with pathological outcome. J Urol 1996; 155: 237A.
8. Henricks WH, England BG, Donald A et al. Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J Urol 1996; 155: 236a.
9. Morete J, Encabo MA, Lopez MA, De Torres IM. The free to total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. BJU Int 1999; 83: 1003-1006.
10. Narayan P, Fournier G, Gajandren V et al. Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 1994; 44: 519-524.
11. Oesterling JE, Brendler CB, Epstein JI et al. Correlation of clinical stage clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987; 92: 138-142.
12. Pannek J, Rittenhouse HG, Chan DW et al. The use of percent free prostatic specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159: 1238-1242.
13. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-114.
14. Partin AW, Catalona WJ, Sothwick PC et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48(6A): 55-61.
15. Partin AW, Kattan MW, Subong ENP et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-1451.
16. Sands ME, Zagars GK, Pollack A, Von Eschenbach AC. Serum prostate specific antigen, clinical stage pathological stage and the incidence of nodal metastases in prostate cancer. Urology 1994; 44: 215-220.
17. Southwick P, Catalona WJ, Partin AW. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial. J Urol 1999; 162: 1346-1351.